Meeting the Standards of Normal Science in Health Outcomes and Market ccess
Meeting the Standards of Normal Science in Health Outcomes and Market ccess
Meeting the Standards of Normal Science in Health Outcomes and Market Access for Pharmaceutical Products and Devices
Meeting the Standards of Normal Science in Health Outcomes and Market Access for Pharmaceutical Products and Devices

Maimon Commentaries

Over the past 3 years, Dr Paul Langley, Director, Maimon Research has published over 40 commentaries in the University of Minnesota Libraries’ journal INNOVATIONS in Pharmacy. The principal focus of these commentaries is on the need to meet the standards of normal science in cost-effectiveness claims. The standards that are critical are:

 

  • All claims made should be credible, evaluable and replicable

  • Modeled claims that are ‘ for approximate information’ only must be rejected

  • Lifetime reference case models driven by assumption are unacceptable

  • All instruments proposed as measures of change must meet Rasch development standards

  • Measures of change must be disease specific, patient centric and focused on a needs fulfillment quality of life construct

Print Print | Sitemap
© Maimon Research LLC